Government Grants
Business Grants
Home Owner Programs
Federal Programs
About Us
Effect of HIV and Substance Use Comorbidity on the Placenta and Maternal Outcomes (R01 Clinical Trial Optional)
Human immunodeficiency virus (HIV) infection is widely prevalent in individuals in the reproductive age group.
Globally, an estimated 1. 3 million people living with HIV (PWH) become pregnant each year (UNAIDS data, 2019).
With the advent of antiretroviral therapy (ART), significant progress has been made in the prevention of vertical transmission of HIV.
However, although ART has clear benefits in preventing vertical transmission, ART regimens are associated with higher rates of preterm birth, stillbirth, and early infant death.
Optimal development and functioning of the placenta are key factors in maintenance of pregnancy and positively corelate with maternal and fetal outcomes.
Despite this, there is considerable paucity of data on the impact of HIV/ART exposure on the placenta.
Even less is known on the impact of HIV/ART exposure on the placenta in pregnant individuals with substance use/misuse.
Globally, an estimated 1. 3 million people living with HIV (PWH) become pregnant each year (UNAIDS data, 2019).
With the advent of antiretroviral therapy (ART), significant progress has been made in the prevention of vertical transmission of HIV.
However, although ART has clear benefits in preventing vertical transmission, ART regimens are associated with higher rates of preterm birth, stillbirth, and early infant death.
Optimal development and functioning of the placenta are key factors in maintenance of pregnancy and positively corelate with maternal and fetal outcomes.
Despite this, there is considerable paucity of data on the impact of HIV/ART exposure on the placenta.
Even less is known on the impact of HIV/ART exposure on the placenta in pregnant individuals with substance use/misuse.
Agency: Department of Health and Human Services
Office: National Institutes of Health
Estimated Funding: $10,000,000
Office: National Institutes of Health
Estimated Funding: $10,000,000
Who's Eligible
Relevant Nonprofit Program Categories
Obtain Full Opportunity Text:
https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-021.html
Additional Information of Eligibility:
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U. S. Territory or Possession.
Full Opportunity Web Address:
http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-021.html
Contact:
Agency Email Description:
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Agency Email:
Date Posted:
2023-10-30
Application Due Date:
Archive Date:
2024-12-21
